New drug duo takes on tough cancers
NCT ID NCT06795412
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 28 times
Summary
This study tests a new drug called PYX-201 combined with pembrolizumab (a standard immunotherapy) in people with advanced solid tumors that have not responded well to other treatments. The main goals are to find the safest dose and see if the combination can shrink tumors or slow their growth. About 220 adults with specific cancers like head and neck, breast, or stomach cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOURS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Léon Bérard
RECRUITINGLyon, 69373, France
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
-
Hopital Saint - Andre - CHU de Bordeaux
RECRUITINGBordeaux, 33075, France
-
Hospital Clínico Universitario de Valencia
RECRUITINGValencia, 46010, Spain
-
Hospital Universitario 12 de Octubre
RECRUITINGMadrid, 28041, Spain
-
Hospital Universitario Ramón y Cajal
RECRUITINGMadrid, 28034, Spain
-
Hospital Universitario Vall d'Hebron
RECRUITINGBarcelona, 08035, Spain
-
Hôpital de la Timone
RECRUITINGMarseille, 13385, France
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
-
NEXT Oncology Houston
RECRUITINGHouston, Texas, 77054, United States
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
-
START Madrid - Hospital Universitario Fundación Jiménez Díaz
RECRUITINGMadrid, 28040, Spain
-
Sarcoma Oncology Center
RECRUITINGSanta Monica, California, 90403, United States
-
University of California San Diego
RECRUITINGSan Diego, California, 92093, United States
-
University of Chicago
RECRUITINGChicago, Illinois, 60637, United States
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
-
University of Pittsburgh Medical Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
-
University of Texas - M.D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.